Lisdexamfetamine (Vyvanse) and Miscarriage Risk
Vyvanse (lisdexamfetamine) has not been shown to be teratogenic for miscarriage risk based on high-quality human evidence, but available data are limited. [1] A large register-based study of pregnancies in women with ADHD found that lisdexamfetamine use during pregnancy was associated with higher adjusted odds of miscarriage compared with no lisdexamfetamine exposure. [2]
Evidence From Regulatory Labeling
The U.S. FDA prescribing information states that limited available data from published literature and postmarketing reports are not sufficient to inform a drug-associated risk for major birth defects and miscarriage. [1]
Observational Pregnancy-Loss Data
A nationwide, register-based case-control study (Norway) assessed miscarriage defined as pregnancy loss before 20 weeks among pregnancies in women with ADHD. [2] Any ADHD medication exposure during pregnancy was associated with increased miscarriage risk (adjusted odds ratio [aOR] 1.60, 95% CI 1.41–1.83). [2] In that study, lisdexamfetamine exposure was associated with increased miscarriage risk (aOR 1.81, 95% CI 1.06–3.10). [2] The study used filled prescriptions as a proxy for exposure, which may not equal actual medication use. [2]
Causality Considerations
Miscarriage is common and can occur for many reasons in any pregnancy, which complicates attributing risk to a specific medication. [3] Filled prescriptions and confounding by underlying maternal illness (eg, ADHD severity, comorbid conditions) can affect observed associations between stimulant use and miscarriage outcomes. [2]
Drug-Related vs Illness-Related Risk
Because lisdexamfetamine is prescribed for ADHD, the underlying indication and associated comorbidities may contribute to pregnancy-loss risk independently of medication exposure. [2] The available evidence supports an association signal rather than proof of causation. [1], [2]
Clinical Risk-Benefit Framing During Pregnancy
Regulatory labeling supports individualized risk-benefit assessment due to insufficient data to quantify miscarriage risk. [1] Prescribing clinicians typically balance maternal functional needs and symptom control against the limits of miscarriage-risk data for lisdexamfetamine. [1]
When Miscarriage Concern Requires Urgent Evaluation
If bleeding, cramping, or other symptoms consistent with pregnancy loss occur, prompt clinical evaluation is indicated to assess viability and rule out other causes. [3]
Counseling and Follow-Up Options
Pregnancy exposure monitoring is available via the National Pregnancy Registry for Psychostimulants for patients exposed to ADHD medications during pregnancy. [1]
Key Points
Lisdexamfetamine has limited human data for miscarriage risk, and FDA labeling states the available evidence is insufficient to determine a medication-associated miscarriage risk. [1] An observational register-based study found increased adjusted odds of miscarriage with lisdexamfetamine exposure during pregnancy in women with ADHD. [2] Causality cannot be concluded from this association due to common background miscarriage risk and potential confounding. [2], [3]